Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 3/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 3/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.33 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.33 |
| ▸ | GSK3A | P49840 | 2/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.33 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4048086 | 0.84 | METAP2 (0.39) | METAP2METAP1EGLN1 | |
| SCHEMBL4048043 | 0.81 | METAP2 (0.37) | METAP2METAP1EGLN1 | |
| SCHEMBL4054698 | 0.79 | ADORA3 (0.40) | METAP2METAP1ADORA3ADORA2AADORA1 | |
| SCHEMBL4046285 | 0.78 | GPR84 (0.35) | METAP2METAP1KDM4E | |
| SCHEMBL4047016 | 0.76 | METAP2 (0.33) | METAP2METAP1 | |
| SCHEMBL4047234 | 0.76 | GPR84 (0.43) | METAP2METAP1GSK3BALDH1A1CDK1 | |
| SCHEMBL13905132 | 0.76 | METAP2 (0.33) | METAP2METAP1 | |
| SCHEMBL24802846 | 0.75 | NR3C1 (0.31) | — | |
| SCHEMBL16691773 | 0.75 | ADORA3 (0.33) | ADORA3ADORA2AADORA1ADORA2BKDM4E | |
| SCHEMBL15457352 | 0.73 | GSK3B (0.37) | ADORA3ADORA2AADORA1ADORA2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| US-10729738-B2 | Hindered disulfide drug conjugates | GENENTECH, INC. (US) | 2020-08-04 | — | — | US | disclosed |
| US-9931407-B2 | Silicon based drug conjugates and methods of using same | BLINKBIO, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | GENENTECH INC (US) | 2017-04-27 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
| US-20140323722-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-8754113-B2 | Oxadiazole derivative having endothelial lipase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2014-06-17 | — | — | US | disclosed |
| US-20120328569-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | MERCK SHARP & DOHME CORP. | 2012-12-27 | — | — | US | disclosed |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| WO-2009029592-A1 | HETEROBICYCLIC-SUBSTITUTED QUINOLONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| WO-2009029592-A1 | HETEROBICYCLIC-SUBSTITUTED QUINOLONES USEFUL AS NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | METAP2 1485/4885METAP1 1280/4885ADORA3 4145/4885 |
| US-20120328569-A1 | INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE | HCCS, EIF2AK2, RNGTT | METAP2 466/4885METAP1 128/4885ADORA3 4408/4885 |
| US-20120253040-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | LIPG, LPL, CEL | METAP2 3145/4885METAP1 2507/4885ADORA3 1464/4885 |
| US-20220411404-A1 | ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB3 | METAP2 1616/4885METAP1 1459/4885ADORA3 1722/4885 |
| US-10729738-B2 | Hindered disulfide drug conjugates | STS, TST, SCLY | METAP2 2321/4885METAP1 2115/4885ADORA3 3833/4885 |
| US-20140323722-A1 | OXADIAZOLE DERIVATIVE HAVING ENDOTHELIAL LIPASE INHIBITORY ACTIVITY | LIPG, CEL, LPL | METAP2 2490/4885METAP1 2169/4885ADORA3 1312/4885 |
| US-20170112891-A1 | HINDERED DISULFIDE DRUG CONJUGATES | STS, TST, SCLY | METAP2 2321/4885METAP1 2115/4885ADORA3 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.